Sort
10,766 grants matching “checkpoint inhibitor”
Exosomes as carriers of cancer therapeutics
$551,888Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2022 · CA
Modulation of the tumor microenvironment with probiotic therapies
$551,862Tal Danino · Columbia Univ New York Morningside · R01 · FY2023 · CA
Exosomes as carriers of cancer therapeutics
$551,771Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2024 · CA
Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
$551,762Michael Karin · University Of California, San Diego · R01 · FY2020 · CA
Congenic Mouse Medels of Melanoma for the Characterization of Tumor Immune Responses
$551,750Marcus W Bosenberg · Yale University · R01 · FY2018 · CA
Congenic Mouse Medels of Melanoma for the Characterization of Tumor Immune Responses
$551,750Marcus W Bosenberg · Yale University · R01 · FY2017 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
$551,629Jie Wu · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2024 · CA
Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancer
$551,601Brian S J Blagg · University Of Notre Dame · R01 · FY2025 · CA
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
$551,399Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2023 · CA
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC
$551,399Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2025 · CA
Ascorbic acid as a pharmacologic agent in disease treatment
$551,249Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Mechanisms Governing Expansion of Embryonic Progenitor Cells (EPCs) inMetaplasia
$551,187Jason C Mills · Baylor College Of Medicine · R01 · FY2023 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
$551,095Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
Innate lymphoid cell regulation of the host-microbiota interactions in cancer
$551,090Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
$551,067John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2021 · CA
Cell type-directed Tim-3 targeting in melanoma
$551,025Steven Russell Barthel · Brigham And Women'S Hospital · R01 · FY2024 · CA
Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment
$551,007Kathryn Miller-Jensen · Yale University · U01 · FY2022 · CA
Congenic Mouse Medels of Melanoma for the Characterization of Tumor Immune Responses
$550,926Marcus W Bosenberg · Yale University · R01 · FY2016 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$550,839Michelle S Bradbury · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment
$550,802Mizuki Nishino · Brigham And Women'S Hospital · R01 · FY2019 · CA
Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
$550,740Michael Karin · University Of California, San Diego · R01 · FY2019 · CA
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy
$550,644Jin-Ming Yang · University Of Kentucky · R01 · FY2023 · CA
Nucleus Accumbens-Associated Protein-1 in Melanoma Immunotherapy
$550,643Jin-Ming Yang · University Of Kentucky · R01 · FY2022 · CA
Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment
$549,997Kathryn Miller-Jensen · Yale University · U01 · FY2023 · CA
Structure-function studies of LAG3 interactions with antibodies and cellular ligands
$549,962Vincent Christopher Luca · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA